UBS Upgrades Moderna to Buy, Lowers Price Target to $191
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Eliana Merle upgraded Moderna (NASDAQ:MRNA) from Neutral to Buy and lowered the price target from $221 to $191.
June 26, 2023 | 9:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's stock rating has been upgraded to Buy by UBS analyst Eliana Merle, with a lowered price target of $191.
The upgrade to Buy indicates a positive outlook for Moderna's stock in the short term. However, the lowered price target suggests a more conservative valuation, which may limit the stock's upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100